Materias dentro de su búsqueda.
Mostrando 4,901 - 4,918 Resultados de 4,918 Para Buscar '"Pfizer"', tiempo de consulta: 0.42s Limitar resultados
  1. 4901
    “…[Figure: see text] DISCLOSURES: Kastritis:  Genesis Pharma: Honoraria; Janssen: Consultancy, Honoraria, Research Funding; Takeda: Honoraria; Pfizer: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Antibody Response after Vaccination for Sars-Cov-2 in Patients with AL Amyloidosis and the Impact of Therapy
  2. 4902
    “…Nikolaenko:  Rafael Pharmaceuticals: Research Funding; Pfizer: Research Funding. Shouse:  Beigene: Honoraria; Kite Pharma: Speakers Bureau. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Use of Monoclonal Antibody Therapy in Hematologic Patients with Mild-to-Moderate COVID-19: A Retrospective Single-Center Experience
  3. 4903
    “…Kastritis:  Amgen: Consultancy, Honoraria, Research Funding; Genesis Pharma: Honoraria; Janssen: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria, Research Funding; Takeda: Honoraria. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Patients with Multiple Myeloma and Prior COVID-19 Have Superior Antibody Responses Against Sars-Cov-2 Compared with Fully Vaccinated Myeloma Patients with the BNT162b2 Vaccine
  4. 4904
    “…Pipe:  Sangamo Therapeutics: Other: Scientific Advisory Board; ASC Therapeutics: Other: Scientific Advisory Board; Apcintex: Consultancy; Bayer: Consultancy; Biomarin: Consultancy; Catalyst Biosciences: Consultancy; CSL Behring: Consultancy; Freeline: Consultancy; Grifols: Consultancy; HEMA Biologics: Consultancy; Novo Nordisk: Consultancy; Octapharma: Consultancy; Pfizer: Consultancy; Roche: Consultancy; Sanofi: Consultancy; Takeda: Consultancy; Spark Therapeutics: Consultancy; uniQure: Consultancy. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Defibrotide Therapy for Sars CoV2 Acute Respiratory Distress Syndrome
  5. 4905
    “…FINDINGS: The total study sample consisted of 185 participants. 65 participants received two doses of mRNA-1273 (Spikevax; Moderna), 36 received two doses of BNT162b2 (Comirnaty; Pfizer–BioNTech), and 84 received mRNA-1273 followed by BNT162b2. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study
  6. 4906
    por Adams, Katherine, Rhoads, Jillian P, Surie, Diya, Gaglani, Manjusha, Ginde, Adit A, McNeal, Tresa, Talbot, H Keipp, Casey, Jonathan D, Zepeski, Anne, Shapiro, Nathan I, Gibbs, Kevin W, Files, D Clark, Hager, David N, Frosch, Anne E, Exline, Matthew C, Mohamed, Amira, Johnson, Nicholas J, Steingrub, Jay S, Peltan, Ithan D, Brown, Samuel M, Martin, Emily T, Lauring, Adam S, Khan, Akram, Busse, Laurence W, Duggal, Abhijit, Wilson, Jennifer G, Chang, Steven Y, Mallow, Christopher, Kwon, Jennie H, Chappell, James D, Halasa, Natasha, Grijalva, Carlos G, Lindsell, Christopher J, Lester, Sandra N, Thornburg, Natalie J, Park, SoHee, McMorrow, Meredith L, Patel, Manish M, Tenforde, Mark W, Self, Wesley H, Ghamande, Shekhar, Calhoun, Nicole, Murthy, Kempapura, Herrick, Judy, McKillop, Amanda, Hoffman, Eric, Zayed, Martha, Smith, Michael, Kozikowski, Lori-Ann, De Souza, Lesley, Ouellette, Scott, Bolstad, Michael, Coviello, Brianna, Ciottone, Robert, Devilla, Arnaldo, Grafals, Ana, Higgins, Conor, Ottanelli, Carlo, Redman, Kimberly, Scaffidi, Douglas, Weingart, Alexander, Lewis, Nathaniel, Mehkri, Omar, Mitchell, Megan, Griffith, Zachary, Brennan, Connery, Ashok, Kiran, Poynter, Bryan, ten Lohuis, Caitlin, Stanley, Nicholas, Zhang, Sophia, Prekker, Matthew, Erickson, Heidi, Hendrickson, Audrey, Caspers, Sean, Tordsen, Walker, Kaus, Olivia, Scharber, Tyler, Lumpkin, Jenna, Smith, Cassie, Marshall, Hunter, Shehu, Arber, Ali, Harith, Rothman, Richard E, Mohamed, Amira, Nair, Rahul, Chen, Jen-Ting (Tina), Karow, Sarah, Robart, Emily, Maldonado, Paulo Nunes, Khan, Maryiam, So, Preston, So, Madison, Schwartz, Elizabeth, Botros, Mena, Hough, Catherine L, Jung, Haeun, Martinez, Jesus, Luong, Andrea, Huynh, Bao, Ibrahim, Habiba, Villanueva-Vargas, Cynthia, Villanueva-Vargas, Juliana, Quadri, Suha, Gordon, Alexandra June, Levitt, Joe, Perez, Cynthia, Visweswaran, Anita, Roque, Jonasel, Qadir, Nida, Frankel, Trevor, Garner, Omai, Chandrasekaran, Sukantha, Douin, David, Jensen, Kelly, Huynh, David, Steinwand, Aimee, Withers, Cori, Mohr, Nicholas, Nassar, Paul, Landers, Shannon, Nielsen, Karin, Briggs, Noble, Fairfield, Cathy, Gershengorn, Hayley, Rivas, Carolina, Monto, Arnold, McSpadden, E J, Truscon, Rachel, Kaniclides, Anne, Thomas, Lara, Bielak, Ramsay, Valvano, Weronika Damek, Fong, Rebecca, Fitzsimmons, William J, Blair, Christopher, Gilbert, Julie, Baker, Leigh, Srinivasan, Vasisht, Crider, Christine D, Steinbock, Kyle A, Paulsen, Thomas C, Anderson, Layla A, Jones, Ian, Womack, Kelsey, Baughman, Adrienne, Kampe, Christy, Johnson, Jakea, Hart, Kim, Rice, Todd, Stubblefield, William B, Zhu, Yuwei, Short, Laura L, Ezzell, Lauren J, Whitsett, Margaret E, McHenry, Rendie E, Hargrave, Samarian J, Blair, Marcia, Luther, Jennifer L, Pulido, Claudia Guevara, Peterson, Bryan P M, LaRose, Mary, Landreth, Leigha, Hicks, Madeline, Parks, Lisa, Babcock, Hilary, Bongu, Jahnavi, McDonald, David, Cass, Candice, Seiler, Sondra, Park, David, Hink, Tiffany, Wallace, Meghan, Burnham, Carey-Ann, Arter, Olivia G
    Publicado 2022
    “…Vaccine effectiveness was higher for a boosted regimen than for a primary series alone for both mRNA vaccines (BNT162b2 (Pfizer-BioNTech): 73% (44% to 87%) for primary series plus two boosters, 64% (55% to 72%) for primary series plus one booster, and 36% (21% to 48%) for primary series alone (P<0.001); mRNA-1273 (Moderna): 68% (17% to 88%) for primary series plus two boosters, 65% (55% to 73%) for primary series plus one booster, and 41% (25% to 54%) for primary series alone (P=0.001)). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study
  7. 4907
    “…Twenty-three pts (85% of total) were vaccinated: 17 (74%) received Pfizer-BioNTech BNT162b2 and 6 (26%) had Moderna mRNA-1273 formulations. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Safety and Efficacy of Sars-Cov-2 Vaccines in Hodgkin Lymphoma Patients Receiving PD-1 Inhibitors
  8. 4908
    “…Hill, MD, Allovir: Advisor/Consultant|Allovir: Grant/Research Support|Century Therapeutics: Advisor/Consultant|Covance/CSL: Advisor/Consultant|Deverra: Grant/Research Support|Eversana Life Science Services, LLC: Advisor/Consultant|GeoVax: Grant/Research Support|Gilead: Advisor/Consultant|Gilead: Grant/Research Support|Karius: Advisor/Consultant|Karius: Grant/Research Support|Merck: Grant/Research Support|Moderna DSMB: Advisor/Consultant|Octapharma AG: Advisor/Consultant|OptumHealth: Advisor/Consultant|Oxford Immunotec: Grant/Research Support|Pfizer (previously Amplyx/Medpace): Advisor/Consultant|Senti BioSciences, Inc: Advisor/Consultant|Symbio: Advisor/Consultant|Takeda: Advisor/Consultant|Takeda: Grant/Research Support|Up-to-Date: Advisor/Consultant…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2711. Viral encephalitis after chimeric antigen receptor (CAR)-modified T-cell therapy: A Retrospective Cohort Study
  9. 4909
    “….: Consultancy, Honoraria, Other: Travel expenses, Research Funding, Speakers Bureau; Janssen: Speakers Bureau; AstraZeneca: Consultancy; Corvus: Research Funding; Rhizen: Research Funding; Pfizer: Research Funding; Kite: Honoraria, Other: Travel expenses, Speakers Bureau; Viracta: Research Funding; Trillium: Research Funding; Bayer: Consultancy, Honoraria; Pharmacyclics: Honoraria, Other, Speakers Bureau; Amgen: Research Funding; Eisai: Research Funding; Cell Medica: Research Funding; Abbvie: Honoraria.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    COVID-19 Impact on Lymphoma Patients' Clinical Outcomes - an Observational Cohort Study
  10. 4910
    “…Godwin:  Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company; Pfizer: Research Funding. Gopal:  Genetech: Consultancy, Honoraria, Research Funding; Karyopharm: Consultancy, Honoraria; Incyte: Honoraria; Acrotech: Consultancy, Honoraria; ADC Therapeutics: Consultancy, Honoraria; Kite: Consultancy, Honoraria; MorphoSys: Honoraria; Epizyme: Consultancy, Honoraria; Gilead: Consultancy, Honoraria, Research Funding; Teva: Research Funding; IGM Biosciences: Research Funding; Bristol Meyers Squibb: Research Funding; Astra-Zeneca: Research Funding; Cellectar: Consultancy, Honoraria; Agios: Research Funding; Takeda: Research Funding; Merck: Consultancy, Honoraria, Research Funding; Servier: Consultancy, Honoraria; I-Mab bio: Consultancy, Honoraria, Research Funding; Nurix Inc: Consultancy, Honoraria; Beigene: Consultancy, Honoraria; SeaGen: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Oral Ixazomib in Untreated Follicular Lymphoma Permits COVID-19 Vaccine Response and Its Efficacy Is Associated with Clinical Factors and Gene Expression Signatures
  11. 4911
    “…METHODS: MM and WM patients are vaccinated with mRNA-1273 (Moderna), BNT162b2 mRNA (Pfizer/BioNTech), or JNJ-78436735 (Johnson & Johnson) in a prospective clinical trial. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
  12. 4912
    “…Dillon:  Menarini: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees, Other: Session chair (paid to institution), Speakers Bureau; Astellas: Consultancy, Other: Educational Events , Speakers Bureau; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Research Support, Educational Events; Amgen: Other: Research support (paid to institution); Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: educational events; Jazz: Other: Education events; Shattuck Labs: Membership on an entity's Board of Directors or advisory committees. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Low Frequency of T Cell and Antibody Responses to Vaccination Against Sars-Cov-2 in Patients Post Allogeneic Stem Cell Transplantation in Comparison with Chronic Myeloid Malignancy Patients
  13. 4913
    “…Confirmed symptomatic COVID‐19 High‐certainty evidence found that BNT162b2 (BioNtech/Fosun Pharma/Pfizer), mRNA‐1273 (ModernaTx), ChAdOx1 (Oxford/AstraZeneca), Ad26.COV2.S, BBIBP‐CorV (Sinopharm‐Beijing), and BBV152 (Bharat Biotect) reduce the incidence of symptomatic COVID‐19 compared to placebo (vaccine efficacy (VE): BNT162b2: 97.84%, 95% CI 44.25% to 99.92%; 2 RCTs, 44,077 participants; mRNA‐1273: 93.20%, 95% CI 91.06% to 94.83%; 2 RCTs, 31,632 participants; ChAdOx1: 70.23%, 95% CI 62.10% to 76.62%; 2 RCTs, 43,390 participants; Ad26.COV2.S: 66.90%, 95% CI 59.10% to 73.40%; 1 RCT, 39,058 participants; BBIBP‐CorV: 78.10%, 95% CI 64.80% to 86.30%; 1 RCT, 25,463 participants; BBV152: 77.80%, 95% CI 65.20% to 86.40%; 1 RCT, 16,973 participants). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Efficacy and safety of COVID‐19 vaccines
  14. 4914
    “…DISCLOSURES: Nathan Archer, PhD, Janssen: Advisor/Consultant|Pfizer: Grant/Research Support Sanjay K. Jain, MD, Fujirebio Diagnostics, Inc., USA: Grant/Research Support|Novobiotic LLC, USA: Grant/Research Support|T3 Pharma, Switzerland: Grant/Research Support.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    983. Pathogen-specific PET/CT imaging for Gram negative implant-associated spinal infections
  15. 4915
    “…Sader, MD, PhD, FIDSA, AbbVie: Grant/Research Support|Basilea: Grant/Research Support|Cipla: Grant/Research Support|Paratek: Grant/Research Support|Pfizer: Grant/Research Support|Shionogi: Grant/Research Support David Andes, MD, Astellas: Advisor/Consultant|Sfunga: Advisor/Consultant…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2552. Comparative Pharmacodynamic Evaluation of Commonly Utilized, Oral, 1(st) - 3(rd) Generation Cephalosporins against S. aureus and E. coli in the Mouse Thigh Infection Model
  16. 4916
    “…Shah:  Pharmacyclics/Janssen: Honoraria, Other: Expenses; Pfizer: Consultancy, Other: Expenses; BeiGene: Consultancy, Honoraria; Servier Genetics: Other; Jazz Pharmaceuticals: Research Funding; Precision Biosciences: Consultancy; Amgen: Consultancy; Kite, a Gilead Company: Consultancy, Honoraria, Other: Expenses, Research Funding; Acrotech/Spectrum: Honoraria; Novartis: Consultancy, Other: Expenses; Bristol-Myers Squibb/Celgene: Consultancy, Other: Expenses; Adaptive Biotechnologies: Consultancy; Incyte: Research Funding. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Immunogenicity of Sars-Cov-2 mRNA 1273 Vaccine in Patients with Lymphoid Malignancies
  17. 4917
    “…Duncan, PhD, AbbVie: Grant/Research Support|Basilea: Grant/Research Support|CorMedix: Grant/Research Support|Melinta: Grant/Research Support|Pfizer: Grant/Research Support Mark E. Jones, PhD, Astellas Pharma Global Development, Inc: Support for the present publication|Basilea Pharmaceutica International Ltd: Employee of Basilea Pharmaceutica International Ltd|Basilea Pharmaceutica International Ltd: Stocks/Bonds Marc Engelhardt, MD, Astellas Pharma Global Development, Inc.: Support for the present publication|Basilea Pharmaceutica International Ltd: Employee of Basilea Pharmaceutica International Ltd|Basilea Pharmaceutica International Ltd: Stocks/Bonds Paul G. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2530. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dose Selection for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Community-Acquired Bacterial Pneumonia (CABP)
  18. 4918
    “…Duncan, PhD, AbbVie: Grant/Research Support|Basilea: Grant/Research Support|CorMedix: Grant/Research Support|Melinta: Grant/Research Support|Pfizer: Grant/Research Support Mark E. Jones, PhD, Astellas Pharma Global Development, Inc: Support for the present publication|Basilea Pharmaceutica International Ltd: Employee of Basilea Pharmaceutica International Ltd|Basilea Pharmaceutica International Ltd: Stocks/Bonds Marc Engelhardt, MD, Astellas Pharma Global Development, Inc.: Support for the present publication|Basilea Pharmaceutica International Ltd: Employee of Basilea Pharmaceutica International Ltd|Basilea Pharmaceutica International Ltd: Stocks/Bonds Paul G. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2531. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dosing Regimens for Patients with Staphylococcus aureus Bacteremia (SAB)
Herramientas de búsqueda: RSS